Wellington reports 3.89M shares (4.76%) in Kymera

Kymera Therapeutics, Inc. Schedule 13G/A amendment shows Wellington group entities reporting shared beneficial ownership of 3,889,687 shares, representing 4.76% of common stock as of 03/31/2026.

Rhea-AI Filing Summary

Kymera Therapeutics, Inc. Schedule 13G/A amendment shows Wellington group entities reporting shared beneficial ownership of 3,889,687 shares, representing 4.76% of common stock as of 03/31/2026. The filing attributes voting and dispositive power to multiple Wellington affiliates and states these shares are owned of record by clients of Wellington investment advisers.

The cover pages list shared voting power of 3,543,178 shares and shared dispositive power of 3,889,687. Signatures by a Compliance Manager are dated 05/15/2026.

Insights

Institutional Ownership Analyst

Wellington reports a 3,889,687-share stake ( 4.76% ) in Kymera as of 03/31/2026.

Wellington's filing lists shared voting power of 3,543,178 and shared dispositive power of 3,889,687, reflecting client-level record ownership through multiple advisory and holding entities. The filing clarifies ownership is held of record by clients of Wellington investment advisers.

Subsequent filings or transactions by those client accounts would determine any change in reported percentages; the disclosure attributes power across several affiliates and includes standard parent/subsidiary mappings.

Compliance & SEC Filings Specialist

This is an amended Schedule 13G filing showing aggregated beneficial ownership among related Wellington entities.

The filing follows Schedule 13G/A conventions: it reports the amount beneficially owned, percent of class (4.76%), and itemizes sole/shared voting and dispositive powers across named entities. It also includes Item 7 subsidiary/affiliate mappings.

Filing signatures are dated 05/15/2026. Changes in voting or dispositive power would appear in future amendments where required by schedule rules.

Key Figures

Shares beneficially owned: 3,889,687 shares Percent of class: 4.76% Shared voting power: 3,543,178 shares +3 more

6 metrics

Shares beneficially owned 3,889,687 shares reported beneficial ownership as of 03/31/2026

Percent of class 4.76% percentage of common stock as reported on cover pages

Shared voting power 3,543,178 shares shared power to vote as listed on cover pages

Shared dispositive power 3,889,687 shares shared power to dispose as listed on cover pages

CUSIP 501575104 Kymera Therapeutics Common Stock CUSIP on cover page

Filing signature date 05/15/2026 Compliance Manager signature date

Key Terms

Schedule 13G/A, beneficial ownership, shared dispositive power, shared voting power

4 terms

Schedule 13G/A regulatory

"Amendment No. 8 and cover pages identifying beneficial ownership"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

beneficial ownership financial

"Item 4(a) Amount beneficially owned: See the responses to Item 9"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

shared dispositive power financial

"Shared Dispositive Power 3,889,687.00 on cover page"

shared voting power financial

"Shared Voting Power 3,543,178.00 on cover page"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Wellington report in Kymera Therapeutics (KYMR)?

Wellington entities report beneficial ownership of 3,889,687 shares, equal to 4.76% of Kymera's common stock as of 03/31/2026. The shares are owned of record by clients of Wellington investment advisers.

Which Wellington affiliates are named on the Schedule 13G/A for KYMR?

The filing lists Wellington Management Group LLP, Wellington Group Holdings LLP, and Wellington Investment Advisors Holdings LLP, plus related advisory entities controlling the client accounts owning the reported shares.

How much voting power does Wellington report for KYMR?

The cover pages disclose shared voting power of 3,543,178 shares and shared dispositive power of 3,889,687 shares, with no sole voting or sole dispositive power reported.

Are the shares held directly by Wellington or by clients?

The filing states the securities are owned of record by clients of the Wellington investment advisers; Wellington reports control/consultative relationships but ownership is at the client level.

What dates are relevant in this Schedule 13G/A amendment?

The statement of beneficial ownership is dated as of 03/31/2026 on the cover pages; the filing signatures are dated 05/15/2026 by the Compliance Manager.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 07:48 AM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 8)

Kymera Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

501575104

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 501575104

1

Names of Reporting Persons

Wellington Management Group LLP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MASSACHUSETTS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,543,178.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,889,687.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,889,687.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.8 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP Number(s): 501575104

1

Names of Reporting Persons

Wellington Group Holdings LLP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,543,178.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,889,687.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,889,687.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.8 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP Number(s): 501575104

1

Names of Reporting Persons

Wellington Investment Advisors Holdings LLP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,543,178.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,889,687.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,889,687.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.8 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Kymera Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 500 North Beacon Street, 4th Floor, Watertown MA 02472
Item 2.
(a)	Name of person filing: Wellington Management Group LLP Wellington Group Holdings LLP Wellington Investment Advisors Holdings LLP
(b)	Address or principal business office or, if none, residence: c/o Wellington Management Company LLP, 280 Congress Street, Boston MA 02210
(c)	Citizenship: Wellington Management Group LLP - Massachusetts Wellington Group Holdings LLP - Delaware Wellington Investment Advisors Holdings LLP - Delaware
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 501575104
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See the responses to Item 9 on the attached cover pages.
(b)	Percent of class: 4.76 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: See the responses to Item 6 on the attached cover pages.
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: See the responses to Item 8 on the attached cover pages.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The securities as to which this Schedule is filed are owned of record by clients of one or more investment advisers identified in Item 7 directly or indirectly owned by Wellington Management Group LLP. Those clients have the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, such securities. No such client is known to have such right or power with respect to more than five percent of this class of securities, except as follows: Not Applicable.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. Pursuant to the instructions in Item 7 of Schedule 13G, the following lists the identity and Item 3 classification of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Wellington Group Holdings LLP - HC Wellington Investment Advisors LLP - HC Wellington Management Global Holdings, Ltd. - HC One or more of the following investment advisers (the "Wellington Investment Advisers"): Wellington Management Company LLP - IA Wellington Management Canada LLC - IA Wellington Management Singapore Pte Ltd - IA Wellington Management Hong Kong Ltd - IA Wellington Management International Ltd - IA Wellington Management Japan Pte Ltd - IA Wellington Management Australia Pty Ltd - IA The securities as to which this Schedule is filed by Wellington Management Group LLP, as parent holding company of certain holding companies and the Wellington Investment Advisers, are owned of record by clients of the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP controls directly, or indirectly through Wellington Management Global Holdings, Ltd., the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP is owned by Wellington Group Holdings LLP. Wellington Group Holdings LLP is owned by Wellington Management Group LLP.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Wellington Management Group LLP

Signature:	Matthew Revell
Name/Title:	Compliance Manager
Date:	05/15/2026

Wellington Group Holdings LLP

Signature:	Matthew Revell
Name/Title:	Compliance Manager
Date:	05/15/2026

Wellington Investment Advisors Holdings LLP

Signature:	Matthew Revell
Name/Title:	Compliance Manager
Date:	05/15/2026